[1]孙来顺.氨磺必利治疗阴性症状为主的精神分裂症患者的疗效[J].医学信息,2021,34(22):136-138.[doi:10.3969/j.issn.1006-1959.2021.22.042]
　SUN Lai-shun.Efficacy of Amisulpride in the Treatment of Schizophrenia Patients with Negative Symptoms[J].Medical Information,2021,34(22):136-138.[doi:10.3969/j.issn.1006-1959.2021.22.042]
点击复制

氨磺必利治疗阴性症状为主的精神分裂症患者的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年22期
页码:
136-138
栏目:
药物与临床
出版日期:
2021-11-15

文章信息/Info

Title:
Efficacy of Amisulpride in the Treatment of Schizophrenia Patients with Negative Symptoms
文章编号:
1006-1959（2021）22-0136-03
作者:
孙来顺
（天津市宝坻区安康医院精神科，天津 301800）
Author(s):
SUN Lai-shun
(Department of Psychiatry,Tianjin Baodi District Ankang Hospital,Tianjin 301800,China)
关键词:
氨磺必利; 阴性症状; 精神分裂症
Keywords:
Amisulpride; Negative symptoms; Schizophrenia
分类号:
R749.3
DOI:
10.3969/j.issn.1006-1959.2021.22.042
文献标志码:
A
摘要:
目的 分析氨磺必利治疗阴性症状为主的精神分裂症患者的临床疗效。方法 选取2019年10月-2020年11月我院收治的86例以阴性症状为主的精神分裂症患者作为研究对象，采用随机数字表法分为A组和B组，各43例。A组给予氨磺必利治疗，B组给予氯氮平治疗，比较两组临床疗效、SANS评分、生活质量以及不良反应发生率。结果 治疗后2、4、8及12周，两组治疗总有效率比较，差异无统计学意义（P＞0.05）；情感淡漠、思维贫乏、意志缺乏、兴趣社交缺乏、注意障碍各因子评分均低于治疗前，且A组低于B组，差异有统计学意义（P＜0.05）。治疗后12周，两组物质生活、躯体健康、心理健康、社会功能评分均高于治疗前，且A组高于B组，差异有统计学意义（P＜0.05）。A组不良反应发生率为25.58%，低于B组的69.77%，差异有统计学意义（P＜0.05）。结论 氨磺必利治疗阴性症状为主的精神分裂症患者具有良好的临床疗效，能在短时间内改善患者临床症状，控制疾病进展，有利于提高患者生活质量，同时安全性较高。
Abstract:
Objective To analyze the clinical efficacy of amsulapride in the treatment of schizophrenic patients with negative symptoms.Methods A total of 86 schizophrenic patients with negative symptoms admitted to our hospital from October 2019 to November 2020 were selected as subjects. They were randomly divided into group A and group B, with 43 cases in each group. Group A was treated with amisulpride, and group B was treated with clozapine. The clinical efficacy, SANS score, quality of life and incidence of adverse reactions were compared between the two groups.Results At 2, 4, 8 and 12 weeks after treatment, there was no significant difference in the total effective rate between the two groups (P>0.05). The scores of emotional indifference, poor thinking, lack of interest, social interaction, and attention disorder were lower than those before treatment, and those in group A were lower than those in group B, and the difference was statistically significant(P<0.05). Twelve weeks after treatment, the scores of physical life, physical health, mental health and social function in the two groups were higher than those before treatment, and those in group A were higher than those in group B, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in group A was 25.58%, which was lower than 69.77% in group B, and the difference was statistically significant (P<0.05).Conclusion Amsulapride has good clinical efficacy in the treatment of schizophrenic patients with mainly negative symptoms, which can improve the clinical symptoms of patients in a short time, control the progression of the disease, and is beneficial to improve the quality of life of patients with high safety.

参考文献/References:

[1]张晓琳,任姣娜,全宏洁.氨磺必利治疗阴性症状为主的精神分裂症临床疗效分析[J].临床心身疾病杂志,2020,26(1):144-145.[2]张志勇,原富强,程德君.奥氮平联合氨磺必利治疗精神分裂症的效果及其对睡眠和认知功能的影响[J].国际精神病学杂志,2020,47(1):43-45,57.[3]Liang Y,Yu X.The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study[J].Neuropsychiatr Dis Treat,2017(13):1163-1173.[4]范悦斌,邱佳琦,李芳,等.阿立哌唑和氨磺必利对女性首发精神分裂症患者性激素的影响研究[J].中国实用医药,2020,15(1):113-115. [5]赵磊.氨磺必利联合重复经颅磁刺激治疗精神分裂症患者的疗效研究[J].中国现代药物应用,2020,14(14):103-104.[6]Reeves S,Eggleston K,Cort E,et al.Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP) [J].Int J Geriatr Psychiatry,2018,33(2):396-404.[7]娄石磊,李萍,王胜强,等.利培酮治疗首发精神分裂症的疗效及对患者心肌标志物水平的影响[J].海南医学,2021,32(5):590-592. [8]钱玉龙,李云峰,陈圆圆.小剂量阿立哌唑联合氨磺必利治疗男性精神分裂症的临床疗效及对催乳素和认知功能的影响[J].临床合理用药杂志,2020,13(24):26-27,30.[9]Barnes TRE,Leeson V,Paton C,et al.Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial[J].Ther Adv Psychopharmacol,2018,8(7):185-197.[10]苏健军.滋阴宁神方联合氨磺必利治疗首发精神分裂症的疗效观察[J].浙江中医杂志,2020,55(10):743.[11]吴金丽,师晴.氯氮平和利培酮治疗难治性精神分裂症的对照研究[J].黑龙江医药,2018,31(5):1059-1061.[12]Johnsen E,Kroken RA,Loberg EM,et al.Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial[J].Lancet Psychiatry,2020,7(11):945-954.[13]任芹,赵有英,姜蕊.氨磺必利联合阿立哌唑对精神分裂症患者心功能及糖脂代谢的影响[J].中国临床医生杂志,2020,48(2):190-193. [14]杨艳芬,钟远惠.氨磺必利与氯氮平对精神分裂症的疗效研究[J].深圳中西医结合杂志,2021,31(3):140-142.[15]聂所成,刘长成,张新风.氨磺必利对老年慢性精神分裂症患者生存质量和主观幸福感的影响[J].中国药物与临床,2016,16(9):1335-1337.

相似文献/References:

[1]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
　CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Medical Information,2018,31(22):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[2]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
　SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Medical Information,2022,35(22):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
[3]王 震.氯氮平与氯丙嗪治疗维持期精神分裂症患者的临床疗效及安全性比较[J].医学信息,2023,36(03):152.[doi:10.3969/j.issn.1006-1959.2023.03.032]
　WANG Zhen.Comparison of Clinical Efficacy and Safety of Clozapine and Chlorpromazine in the Treatment of Patients with Maintenance Schizophrenia[J].Medical Information,2023,36(22):152.[doi:10.3969/j.issn.1006-1959.2023.03.032]
[4]孙来顺.氨磺必利与利培酮治疗精神分裂症阴性症状的疗效比较[J].医学信息,2022,35(07):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]
　SUN Lai-shun.Comparison of Therapeutic Effects of Amisulpride and Risperidone on Negative Symptoms of Schizophrenia[J].Medical Information,2022,35(22):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]

更新日期/Last Update: 1900-01-01